WO2007077217A2 - Oligopeptide-free cell culture media - Google Patents
Oligopeptide-free cell culture media Download PDFInfo
- Publication number
- WO2007077217A2 WO2007077217A2 PCT/EP2007/000027 EP2007000027W WO2007077217A2 WO 2007077217 A2 WO2007077217 A2 WO 2007077217A2 EP 2007000027 W EP2007000027 W EP 2007000027W WO 2007077217 A2 WO2007077217 A2 WO 2007077217A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- virus
- medium
- cell culture
- oligopeptide
- Prior art date
Links
- 239000006143 cell culture medium Substances 0.000 title claims abstract description 40
- 239000002609 medium Substances 0.000 claims abstract description 67
- 241000700605 Viruses Species 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 229920000768 polyamine Polymers 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims description 144
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 68
- 239000005700 Putrescine Substances 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 108010038807 Oligopeptides Proteins 0.000 claims description 21
- 102000015636 Oligopeptides Human genes 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 18
- 210000003501 vero cell Anatomy 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 15
- 108010054218 Factor VIII Proteins 0.000 claims description 14
- 102000001690 Factor VIII Human genes 0.000 claims description 14
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 14
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 14
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 11
- 241000287828 Gallus gallus Species 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 8
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 8
- 229960003104 ornithine Drugs 0.000 claims description 8
- 108010024636 Glutathione Proteins 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 229960003180 glutathione Drugs 0.000 claims description 7
- 229940063675 spermine Drugs 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 208000007089 vaccinia Diseases 0.000 claims description 5
- 108091005670 ADAMTS13 Proteins 0.000 claims description 4
- 102000043853 ADAMTS13 Human genes 0.000 claims description 4
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
- 108010076282 Factor IX Proteins 0.000 claims description 4
- 108010023321 Factor VII Proteins 0.000 claims description 4
- 108090001126 Furin Proteins 0.000 claims description 4
- 102000004961 Furin Human genes 0.000 claims description 4
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims description 4
- 241000710886 West Nile virus Species 0.000 claims description 4
- 241000710772 Yellow fever virus Species 0.000 claims description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940105774 coagulation factor ix Drugs 0.000 claims description 4
- 229940105778 coagulation factor viii Drugs 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 4
- 229940051021 yellow-fever virus Drugs 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 229940105772 coagulation factor vii Drugs 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims description 2
- 241000712891 Arenavirus Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 241000709721 Hepatovirus A Species 0.000 claims description 2
- 241000712431 Influenza A virus Species 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241000710942 Ross River virus Species 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 229940063673 spermidine Drugs 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 2
- 102100036537 von Willebrand factor Human genes 0.000 claims description 2
- 241000713196 Influenza B virus Species 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 21
- 230000012010 growth Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 15
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 229960000301 factor viii Drugs 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 108010009736 Protein Hydrolysates Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 229940031098 ethanolamine Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003531 protein hydrolysate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- -1 for example Proteins 0.000 description 5
- 239000000413 hydrolysate Substances 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000012365 batch cultivation Methods 0.000 description 4
- 230000000035 biogenic effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000011053 TCID50 method Methods 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 241000865080 Dermacentor albipictus Species 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/005—Protein-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide- free cell culture media comprising at least 0.5 mg/L of a polyamine.
- the invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
- Cell culture media formulations have been supplemented with a range of additives, including undefined components like fetal calf serum (FCS), several animal derived proteins and/or protein hydrolysates of bovine origin as well as protein hydrolysates derived from plants or yeast.
- FCS fetal calf serum
- serum or serum-derived substances such as e.g. albumin, transferrin or insulin
- human serum derived additives have to be tested for all known viruses, including hepatitis viruses and HIV which can be transmitted via serum.
- bovine serum and products derived thereof bear the risk of BSE contamination.
- all serum-derived products can be contaminated by unknown substances.
- Such serum-free media have been developed on the basis of protein extracts derived from plants or yeast.
- soy hydrolysates are known to be useful for fermentation processes and can enhance the growth of many fastidious organisms, yeasts and fungi.
- WO 96/26266 describes that papaic digests of soy meal are a source of carbohydrate and nitrogen and many of the components can be used in tissue culture.
- Franek et al. Biotechnology Progress (2000) 16, 688 - 692 describe growth and productivity promoting effects of defined soy and wheat hydrolysate peptide fractions.
- WO 96/15231 discloses a serum-free medium composed of a synthetic minimal essential medium and a yeast extract for the propagation of vertebrate cells and a virus production process.
- a medium formulation composed of a basal cell culture medium comprising a rice peptide and an extract of yeast and an enzymatic digest thereof, and/or a plant lipid for growth of animal cells is disclosed in WO 98/15614.
- a medium comprising purified soy hydrolysate for the cultivation of recombinant cells is disclosed in WO 01/23527.
- WO 00/03000 discloses a medium that comprises a soy hydrolysate and a yeast extract, but also requires the presence of recombinant forms of animal proteins, such as growth factors.
- EP-A-O 481 791 describes a biochemically defined culture medium for culturing engineered CHO cells, which is free from protein, lipid and carbohydrate isolated from an animal source, further comprising a recombinant insulin or insulin analogue, 1 % to 0.025 % w/v papain digested soy peptone and putrescine.
- WO 98/08934 describes a serum-free eukaryotic cell culture comprising hydrolyzed soy peptides (1 - 1000 mg/L), 0.01 to 1 mg/L putrescine and a variety of animal-derived components, including albumin, fetuin, various hormones and other proteins.
- putrescine is also known to be comprised in standard media like DMEM/Ham's F12 in a concentration of 0.08 mg/L.
- the media known in the state of the art are supplemented with proteins or peptide extracts derived from animals, plants, or yeast; or with recombinant versions of proteins, such as, for example, insulin, insulin like growth factor or other growth factors.
- a further object of the present invention is to provide methods for cultivating cells in said media as well as methods for efficient expression of recombinant proteins and/or methods for the efficient production of viruses.
- the addition of at least 0.5 mg/L of a polyamine to cell culture media provides an advantageous effect not only by promoting cell growth but also by increasing the protein and/or virus expression per cell. Said unexpected advantageous effect can be achieved even in oligopeptide-free media.
- the oligopeptide-free medium according to the present invention allows consistent cell growth and increased yield of desired products, particularly of target proteins such as recombinant proteins and/or viruses, independent of the quality or lot variations of any protein hydrolysates.
- the specific supplementation of cell culture media with a specific concentration of polyamines acts to increase cell growth, cell specific productivity and final cell density.
- the media according to the present invention are more favorable for recombinant protein expression, virus production and cell growth rate compared to the media known in the art. Furthermore, the oligopeptide-free medium according to the present invention obviates the addition of protein hydrolysate to the cell culture medium.
- Figure 1 shows a graph which describes the effect of the addition of 2.0 mg/L putrescine.2HCI on the volumetric FVIII-CoA productivity, expressed in [Units per Liter per Day], of GD8/6 cells cultivated in BAV-medium over the culture time, expressed in [days].
- Arrow Day 11 : Addition of Putrescine.2HCI (2.0 mg/l)
- Figure 2 shows a table which compares the effect of the addition of putrescine optionally in combination with the additional supplementation with Fe (II) and Cu (II) on the volumetric and cell specific productivity (QP, expressed in [Units per Liter per Day], qp, expressed in [mU per 10E06 cells per day]) and on the specific growth rate ⁇ , expressed as specific growth rate per day in [d '1 ] of GD8/6 cells cultivated in BAV-medium.
- QP expressed in [Units per Liter per Day]
- qp expressed in [mU per 10E06 cells per day]
- ⁇ expressed as specific growth rate per day in [d '1 ] of GD8/6 cells cultivated in BAV-medium.
- Figure 3 shows a table which compares the effect of putrescine and/or ornithine on the specific growth rate ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, expressed in [mU per 10E06 cells per day], qp relative, expressed in %) of GD8/6 cells cultivated in BAV-medium.
- Figure 4 shows a table which compares the effect of putrescine and spermine on the specific growth rate ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, qp relative) of GD8/6 cells cultivated in BAV-medium.
- Figure 5 shows a table which compares the effect of putrescine and ethanolamine on the specific growth ( ⁇ absolute, ⁇ relative) and the cell specific productivity (qp absolute, qp relative) of GD8/6 cells cultivated in BAV-medium.
- Figure 6 shows a graph which describes the effect of the addition of 3.6 mg/L putrescine.2HCI on the average MVA virus titer, expressed in [TCID50/ml x 10 8 ].
- - without addition of Putrescine
- Putr. with addition of 3.6 mg/L putrescine.2HCI.
- Figure 7 shows a graph which describes the effect of the addition of various concentrations of putrescine.2HCI, expressed in [mg/l], on the average MVA virus titer, expressed in [TCID50/ml x 10 8 ].
- One aspect of the invention relates to an oligopeptide-free cell culture medium comprising at least 0.5 mg/L of a polyamine.
- polyamine refers to any of the group of biogenic polyamines, which are organic polycations derived from aromatic or cationic amino acids. Polyamines are composed of carbon, nitrogen, and hydrogen and comprise two or more amino groups. Polyamines have one or more positive charges and a hydrophobic skeleton.
- the term encompasses, for example, molecules selected from the group consisting of cadaverine, putrescine, spermidine, spermine, agmatine, ornithine, and combinations thereof.
- the oligopeptide-free culture medium comprises ornithine, or putrescine, or spermine, or combinations thereof.
- the polyamine originates from a source other than a protein hydrolysate.
- the polyamine is synthetically produced.
- the polyamine concentration is at least about 0.5 mg/L, in another embodiment at least about 1 mg/L, in a further embodiment at least about 2 mg/L, in still another embodiment at least 5 mg/L, in yet another embodiment at least 8 mg/L, and in a further embodiment at least 10 mg/L.
- the polyamine concentration ranges from about 0.5 mg/L to about 30 mg/L, in another embodiment from about 0.5 mg/L to about 20 mg/L, in a further embodiment from about 1.0 mg/L to about 20 mg/L, in a further embodiment from about 2.0 mg/L to about 20 mg/L, in a further embodiment from about 2 mg/L to about 10 mg/L, in an alternative embodiment from about 2 mg/L to about 8 mg/L, and in a further embodiment from about 2 mg/L to about 5 mg/L in the medium.
- concentrations indicated above are the respective concentrations of pure polyamine. If a polyamine derivative or a polyamine comprising compound is used, the concentration of the polyamine-group is in the above specified ranges. For example, 2 mg/L Putrescine.2HCI is equivalent to a Putrescine concentration of about 1.095 mg/L (without .2HCI).
- oligopeptide-free cell culture medium refers to a protein-free medium that does not comprise oligopeptides, such as e.g. oligopeptides derived from a protein hydrolysate. In one embodiment, the medium does not comprise oligopeptides having twenty or more amino acids. In one embodiment of the present invention, the medium does not comprise oligopeptides having fifteen or more amino acids. In another embodiment of the invention, the medium does not comprise oligopeptides having ten or more amino acids.
- the medium does not comprise oligopeptides having seven or more amino acids, in another embodiment it does not comprise oligopeptides having five or more amino acids, in still another embodiment it does not comprise oligopeptides having three or more amino acids. According to a further embodiment of the present invention, the medium does not comprise oligopeptides having two or more amino acids.
- the medium according to the invention may optionally comprise glutathione and/or at least one stable form of glutamine, such as, e.g., L-alanyl-L-glutamine.
- glutathione as used herein describes a tripeptide composed of the amino acids glutamate, cysteine and glycine including the oxidized form of glutathione, i.e. glutathione disulfide, a glutathione dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.
- the oligopeptide-free cell culture medium does not comprise oligopeptides having three or more amino acids, but may optionally comprise glutathione.
- the oligopeptide-free cell culture medium does not comprise oligopeptides having two or more amino acids, but may optionally comprise glutathione and/or at least one stable form of glutamine.
- Typical proteins and/or oligopeptides that are avoided in the media according to the invention are those found in serum and serum-derived substances, such as e.g. albumin, transferrin, insulin or other growth factors as well as recombinant forms thereof, or oligopeptides from plant or yeast hydrolysates or ultrafiltered forms thereof.
- the oligopeptide-free culture medium according to the invention may be based on any basal medium such as DMEM, Ham's F12, Medium 199, McCoy, or RPMI generally known to a person skilled in the art.
- the basal medium may comprise a number of ingredients, including amino acids, vitamins, organic and inorganic salts, and sources of carbohydrate, each ingredient being present in an amount which supports the cultivation of a cell, said amounts being generally known to a person skilled in the art.
- the medium may comprise auxiliary substances, such as buffer substances, e.g., sodium bicarbonate, antioxidants, stabilisers to counteract mechanical stress, or protease inhibitors.
- a non-ionic surfactant such as copolymers and/or mixtures of polyethylene glycols and polypropylene glycols (e.g. Pluronic F68 ® , SERVA) can be added.
- the polyamine controls DNA- and RNA-synthesis, and/or cell proliferation, and/or cell differentiation, and/or membrane stabilization, and/or antioxidative DNA-protection.
- the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium increases the protein and/or virus expression in the cultured cells.
- the protein expression or virus titer in the cultured cells can be increased by at least 50% by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium. In still another embodiment said increase is at least 60%.
- the cell specific productivity is increased at least two-fold by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium; in another embodiment the cell specific productivity is increased at least three-fold.
- the addition of at least 0.5 mg/L of a polyamine results in an increase in protein expression and/or virus titer to at least 400%; in a further embodiment to at least 500%; in another embodiment to at least 600%; in a further embodiment to at least 700%.
- the specific growth rate of the cultured cells can be increased by the addition of at least 0.5 mg/L of a polyamine to an oligopeptide-free cell culture medium. In a further embodiment, said specific growth rate can be increased by 10%. In still another embodiment, said specific growth rate can be increased by 20%. In yet another embodiment, said specific growth rate can be increased by 50%. In a further embodiment, said specific growth rate can be increased by 70%. In another embodiment, said specific growth rate can be increased by 80%. In still another embodiment, said specific growth rate can be increased by 90%. In yet another embodiment, said specific growth rate can be increased by 100%. [033] In a further embodiment of the present invention, the medium is chemically defined.
- chemically defined shall mean, that the medium does not comprise any undefined supplements, such as, for example, extracts of animal components, organs, glands, plants, or yeast. Accordingly, each component of a chemically defined medium is accurately defined.
- the present invention further relates to a method for cultivating cells, comprising the steps of:
- the present invention is not limited to any type of cells.
- Examples of cell types include mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells.
- the cells may be for example stem cells or recombinant cells transformed with a vector for recombinant gene expression, or cells transfected with a virus for producing viral products.
- the cells may also be for example cells producing a protein of interest without recombinant transformation, e.g. a B-cell producing an antibody, which may be transformed into an immortalized status e.g. by viral infection like Epstein Barr Virus infection.
- the cells may also be for example primary cells, e.g. chicken embryo cells, or primary cell lines. Useful are cells that are used for in vitro virus production.
- useful cells include BSC cells, LLC-MK cells, CV-1 cells, COS cells, VERO cells, MDBK cells, MDCK cells, CRFK cells, RAF cells, RK cells, TCMK-1 cells, LLCPK cells, PK15 cells, LLC-RK cells, MDOK cells, BHK-21 cells, CHO cells, NS-1 cells, MRC- 5 cells, WI-38 cells, BHK cells, 293 cells, RK cells, Per.C6 cells and chicken embryo cells.
- the cells used according to the present invention may be cultivated e.g. by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostate-cultivation, all of which are generally known in the field.
- the present invention further relates to a method for expressing at least one protein, such as e.g.
- a heterologous or autologous protein or a recombinant protein comprising the steps of: a) providing a culture of cells; b) introducing at least one nucleic acid sequence comprising a sequence coding for at least one protein into the cells; c) selecting the cells carrying the nucleic acid sequence; and d) expressing the protein in the cells in a medium comprising at least 0.5 mg/L of a polyamine.
- the medium of step d) is an oligo- peptide-free medium according to the present invention.
- the cells of the culture of step a) have been grown in an oligopeptide- free cell culture medium according to the present invention.
- steps a) to d) are conducted in an oligopeptide-free cell culture medium according to the invention.
- the nucleic acid sequence comprising a sequence coding for at least one protein may be a vector.
- the vector may be delivered by a virus or may be a plasmid.
- the nucleic acid sequence coding for the protein may be a specific gene or a biologically functional part thereof.
- the protein is at least a biologically active part of a blood coagulation factor such as Factor VIII or at least a biologically active part of a protein involved in the production of red blood cells and angiogenesis such as erythropoeitin, or a monoclonal antibody.
- the nucleic acid sequence comprises a sequence coding for at least one protein selected from the group of coagulation factor VII, coagulation factor VIII, coagulation factor IX, vWF, ADAMTS13, and furin.
- the nucleic acid further comprises other sequences suitable for a controlled expression of a protein such as promotor sequences, enhancers, TATA boxes, transcription initiation sites, polylinkers, restriction sites, poly-A-sequences, protein processing sequences, selection markers, and the like which are generally known to a person skilled in the art.
- the cells are selected from the group of CHO cells, 293 cells, and BHK cells.
- the following cell lines may be transformed with a recombinant vector for the expression of the respective products: CHO cells for the production of recombinant coagulation factors, for example factor VII, and/or factor VIII, and/or monoclonal antibodies, BHK cells for the production of recombinant erythropoietin, Epstein Barr virus transformed, immortalized human B cells for the production of human antibodies.
- recombinant coagulation factors for example factor VII, and/or factor VIII, and/or monoclonal antibodies
- BHK cells for the production of recombinant erythropoietin
- Epstein Barr virus transformed immortalized human B cells for the production of human antibodies.
- Useful cell/ protein combinations are, for example, CHO cells/coagulation factor VIII, CHO cells/coagulation factor VII, CHO cells/ADAMTS13, CHO cells/furin, and 293 cells/ coagulation factor IX.
- the expression of the at least one protein by cells being cultivated in a medium according to the present invention is increased when compared to the expression of the protein by cells not being cultivated in a medium of the present invention.
- said expression is increased for at least 10%, according to a further embodiment for at least 50%.
- the present invention further relates to a method for producing at least one virus or at least one part of a virus, comprising the steps of: a) providing a culture of cells; b) infecting the cells with at least one virus; c) selecting the virus-infected cells; and d) propagating the at least one virus in the cells in a medium comprising at least 0.5 mg/L of a polyamine.
- the medium of step d) is an oligo- peptide-free medium according to the present invention.
- the cells of the culture of step a) have been grown in an oligopeptide- free cell culture medium according to the present invention.
- steps a) to d) are conducted in an oligopeptide-free cell culture medium according to the invention.
- the virus used in the method according to the invention may be any virus, such as, for example, poxviruses, for example vaccinia or attenuated vaccinia viruses; coronaviruses, for example SARS virus; orthomyxoviruses, for example influenza A or B virus; paramyxoviruses; retroviruses, for example Lenti virus; togaviruses, for example Ross River virus; flaviviruses, for example West Nile virus, Yellow Fever Virus, or FSME virus (i.e. tick borne encephalitis virus); enteroviruses, for example hepatitis A virus; picornaviruses; arenaviruses; herpesviruses; or adenoviruses.
- the virus is Modified Vaccinia Virus Ankara (MVA).
- the virus can be propagated according to the invention for the production of a respective vaccine.
- the virus may be a wild-type-virus, an attenuated virus, a reassortant virus, or a recombinant virus or combinations thereof, e.g. attenuated and recombinant.
- an infectious nucleic acid clone may be used instead of actual virions being used to infect cells with a virus.
- Split virions may also be used instead of actual virions being used to infect cells with a virus.
- the method for producing a virus may be used for producing immunogenic compositions comprising a virus, a virus antigen, or a virus-like-particle.
- the cells used in the method for producing a virus according to the present invention may be selected from the group consisting of mammalian cells, insect cells, avian cells, bacterial cells, and yeast cells. In one embodiment, the cells used in the method for producing a virus according to the present invention are selected from the group consisting of Vero cells and chicken embryo cells.
- Useful combinations of cells with viruses for producing a virus or part of a virus are, for example, Vero cell/attenuated vaccinia, Vero cell/Vaccinia, Vero cell/Hepatitis A, Vero cell/ Influenza Virus, Vero cell/West Nile Virus, Vero cell/SARS Virus, Vero cell/Yellow Fever Virus, and chicken embryo cells/FSME virus.
- the cell/virus combination is chicken embryo cells/Modified Vaccinia Virus Ankara (MVA).
- Useful cultivation methods include batch-cultivation, feed-batch-cultivation, perfusion cultivation and chemostat-cultivation.
- Oligopeptide-free medium (BAV-medium) was prepared with basal DMEM/HAM's F12 (1 :1) medium comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were L-glutamine ( 600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic ® (SERVA) (0.25 g/L), sodium selenite (50 nM).
- ⁇ D + In (X t /X0)/t
- Factor VIII Factor VIII
- Figures 1 to 5 The activity of Factor VIII (FVIII) (cf. Figures 1 to 5) was measured by a chromogenic assay (Chromogenic, Sweden).
- the volumetric productivity (QP) is calculated from the amount of activity units yielded per liter reactor volume per day (DIUd) in the production system.
- the cell specific productivity is defined as the specific amount of produced protein (U or ⁇ g) per number of cells per day.
- Cell cultures of recombinant mammalian cells e.g. CHO-cells stably expressing Factor VIII 1 such as GD8/6 cells
- the culture conditions of 37 0 C, oxygen saturation 20%, and pH 7.0 to 7.1 were kept constant.
- the cultures were supplied with a constant feed of BAV-medium.
- Example 6 Effect of the addition of a polvamine on FVIII expression GD8/6 cells were grown in chemostat culture in a 10 L bioreactor as described in Example 5 with a continuous feed of BAV-medium for 11 days, resulting in a decreased productivity of ⁇ 100U/L/d.
- putrescine.2HCI 2 mg/L
- the volumetric FVIII- expression increased by 800% (cf. Figure 1 ). Accordingly, putrescine could be clearly identified as the driving factor of cell specific expression for the GD8/6 cell line.
- Example 7 Effect of the addition of a polyamine and Fe (II) and Cu (II) on FVIII expression
- GD8/6 cells were grown in chemostat culture in a 10 L bioreactor as described in Example 5, resulting in an average productivity of 271 U/L/D, with low cell specific productivity and specific growth rates.
- Putrescine.2HCI 2mg/L
- the FVIII expression increased to 870 U/L/D, mainly due to an increased cell specific productivity.
- Additional supplementation with Fe (II) and Cu (II) in a concentration as it is otherwise typically comprised in soy hydrolysates was leading to an increased specific growth rate of approximately 0.60 d ' ⁇ and an increase of the cell specific productivity to over 1700 mU/10E06 cells/day could be achieved. Under these conditions a volumetric productivity of over 2685 U/L/D was reached.
- a further increase of the cell density resulted in a volumetric productivity of over 3000 U/L/D.
- the maximum volumetric productivity of a soy hydrolysate comprising medium under comparable fermentation conditions was 2000 to 2500 U/L/D, indicating that a chemically defined medium comprising only Putrescine and 2 additional metal ions is superior to any soy hydrolysate comprising medium formulation investigated in this process before (cf. Figure 2).
- Example 9 Effect of the addition of several polvamines and combinations of polvamines on FVIII expression
- GD8/6 cells from a culture with BAV-medium as described in Example 8 were centrifuged and transferred to Techne Spinner flasks with a working volume of 200 ml and incubated at a cell density of about 1-2E06 cell/ml with defined medium, supplemented with ethanolamine, putrescine, ornithine, and/or spermine as indicated in Figures 3, 4, and 5.
- Ornithine which is a precursor of putrescine in the pathway of biogenic amines, could partially substitute putrescine in a concentration-dependent manner.
- the addition of ornithine at different concentrations to the media comprising putrescine.2HCI resulted in an additional increase of specific FVIII productivities and growth rates (cf.
- Example 10 Effect of the addition of a polvamine on MVA virus production
- Primary cell cultures of chicken embryos were cultivated in Techne spinner flasks (working volume 200 ml) using a peptide free medium (FM-Medium) without and with supplementation of 3.6 mg/L Putrescine.2 HCI.
- FM medium was prepared with basal M199 medium comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 31150 Powder). Also added were NaHCO3 (ad 4.4 g/L), Gentamycin.SO4 (50 ⁇ g/L) and Neomycin. SO4 (50 ⁇ g/L).
- Example 11 Effect of the addition of several doses of a polvamine on MVA virus production
- Primary cell cultures of chicken embryos were cultivated in Techne spinner flasks (working volume 200 ml) using a peptide free medium (CEM-Medium) without and with supplementation of 3.6 and 9 mg/L Putrescine.2 HCI.
- CEM medium was prepared with basal DMEM/HAM's F12 (1 :1 ) medium comprising inorganic salts, amino acids, vitamins and other components (Life technologies, 32500 Powder). Also added were NaHCO3 (2 g/L) L-glutamine ( 600 mg/L), ascorbic acid (20 ⁇ M), ethanol amine (25 ⁇ M), Synperonic ® (SERVA) (0.25 g/L), sodium selenite (50 nM), FeSO4.7H2O (600 ⁇ g/L), Gentamycin.SO4 (50 ⁇ g/L) and Neomycin.SO4 (50 ⁇ g/L) . Additionally essential amino acids were supplemented to the cell culture medium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008548995A JP5259418B2 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide cell culture medium |
AU2007204044A AU2007204044B2 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
KR1020087018889A KR101423344B1 (en) | 2006-01-04 | 2007-01-03 | A Method Of Expressing A Protein Using Oligopeptide-Free Cell Culture Media |
DK07702574.0T DK1974014T3 (en) | 2006-01-04 | 2007-01-03 | OLIGOPEPTID-FREE CELL CULTURE MEDIA |
EP16183987.3A EP3121266B8 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
EP07702574.0A EP1974014B1 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
PL16183987T PL3121266T3 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
EP19214402.0A EP3653699A1 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
CA002633306A CA2633306A1 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
RU2008131953/10A RU2486236C2 (en) | 2006-01-04 | 2007-01-03 | Method of protein expression |
KR1020137022322A KR101422435B1 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
LTEP07702574.0T LT1974014T (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
ES07702574.0T ES2629304T3 (en) | 2006-01-04 | 2007-01-03 | Cell culture medium without oligopeptides |
CY20171100596T CY1119046T1 (en) | 2006-01-04 | 2017-06-07 | CELLULAR MEDICINE WITHOUT OLIGEPTECTS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75641906P | 2006-01-04 | 2006-01-04 | |
US60/756,419 | 2006-01-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007077217A2 true WO2007077217A2 (en) | 2007-07-12 |
WO2007077217A3 WO2007077217A3 (en) | 2007-11-08 |
Family
ID=37942126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/000027 WO2007077217A2 (en) | 2006-01-04 | 2007-01-03 | Oligopeptide-free cell culture media |
Country Status (18)
Country | Link |
---|---|
US (4) | US20070212770A1 (en) |
EP (4) | EP3653699A1 (en) |
JP (6) | JP5259418B2 (en) |
KR (2) | KR101422435B1 (en) |
CN (2) | CN101360820A (en) |
AU (1) | AU2007204044B2 (en) |
CA (1) | CA2633306A1 (en) |
CY (1) | CY1119046T1 (en) |
DK (3) | DK2522717T3 (en) |
ES (3) | ES2629304T3 (en) |
HK (1) | HK1177950A1 (en) |
HU (1) | HUE032744T2 (en) |
LT (1) | LT1974014T (en) |
PL (3) | PL1974014T3 (en) |
PT (3) | PT1974014T (en) |
RU (3) | RU2486236C2 (en) |
SI (1) | SI2522717T1 (en) |
WO (1) | WO2007077217A2 (en) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087087A1 (en) * | 2008-01-09 | 2009-07-16 | Cellca Gmbh | Improved culture media additive and process for using it |
WO2011014838A1 (en) | 2009-07-31 | 2011-02-03 | Baxter International Inc. | Cell culture medium for adamts protein expression |
JP2011507551A (en) * | 2007-12-27 | 2011-03-10 | バクスター・インターナショナル・インコーポレイテッド | Cell culture process |
WO2011035335A2 (en) | 2009-09-21 | 2011-03-24 | Baxter International Inc. | Stabilized liquid and lyophilized adamts13 formulations |
WO2012006591A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE |
WO2014144198A1 (en) * | 2013-03-15 | 2014-09-18 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
EP2356247B1 (en) | 2008-11-12 | 2015-07-15 | Baxter International Inc. | Method of producing serum-free insulin-free factor vii |
US9365645B1 (en) | 2011-04-27 | 2016-06-14 | Abbvie, Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9499616B2 (en) | 2013-10-18 | 2016-11-22 | Abbvie Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9522953B2 (en) | 2013-10-18 | 2016-12-20 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9550826B2 (en) | 2013-11-15 | 2017-01-24 | Abbvie Inc. | Glycoengineered binding protein compositions |
EP1974014B1 (en) | 2006-01-04 | 2017-04-19 | Baxalta Incorporated | Oligopeptide-free cell culture media |
EP2906683B1 (en) | 2012-10-15 | 2017-05-31 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
US9683033B2 (en) | 2012-04-20 | 2017-06-20 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9688752B2 (en) | 2013-10-18 | 2017-06-27 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9708400B2 (en) | 2012-04-20 | 2017-07-18 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9708399B2 (en) | 2013-03-14 | 2017-07-18 | Abbvie, Inc. | Protein purification using displacement chromatography |
EP2971040B1 (en) | 2013-03-14 | 2018-09-19 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US10221400B2 (en) | 2009-07-31 | 2019-03-05 | Baxalta GmbH | Method of producing a polypeptide or virus of interest in a continuous cell culture |
EP2563903B1 (en) | 2010-04-26 | 2019-08-21 | Novartis AG | Improved cell culture medium |
WO2019204721A1 (en) | 2018-04-20 | 2019-10-24 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for produring anti-tnf antibody compositions |
WO2020100073A1 (en) | 2018-11-13 | 2020-05-22 | Janssen Biotech, Inc. | Control of trace metals during production of anti-cd38 antibodies |
WO2020183418A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
US10927342B2 (en) | 2015-08-04 | 2021-02-23 | Regeneran Pharmaceuticals, Inc. | Taurine supplemented cell culture medium and methods of use |
JPWO2021090888A1 (en) * | 2019-11-05 | 2021-05-14 | ||
WO2021112927A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
WO2021198781A2 (en) | 2020-04-02 | 2021-10-07 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
WO2023281466A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023167850A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2240578B1 (en) * | 2007-12-31 | 2019-03-20 | Baxalta GmbH | Substantially animal protein-free recombinant furin and methods for producing same |
KR101445433B1 (en) | 2008-02-25 | 2014-09-26 | 백스터 인터내셔널 인코포레이티드 | Method for producing continuous cell lines |
EA027353B1 (en) | 2010-09-17 | 2017-07-31 | Баксалта Инкорпорейтид | STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL pH |
JP6122780B2 (en) | 2010-10-27 | 2017-04-26 | バクスアルタ ゲーエムベーハー | FVIII peptides for immune tolerance induction and immunodiagnosis |
EP3858375B1 (en) | 2011-06-10 | 2024-03-20 | Takeda Pharmaceutical Company Limited | Treatment of coagulation disease by administration of recombinant vwf |
KR101641655B1 (en) * | 2014-01-08 | 2016-07-21 | 서울대학교산학협력단 | Method for cultivation of yeast with the tolerance against growth inhibitor by using spermidine or spermine |
JP6801930B2 (en) * | 2015-03-17 | 2020-12-16 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | Process for the preparation of diaminobutane |
AU2016363789B2 (en) | 2015-12-02 | 2022-06-02 | CSL Behring Lengnau AG | Improved media for the expression of recombinant vitamin K-dependent proteins |
CN106635953B (en) * | 2016-12-13 | 2021-02-19 | 昆明润什生物科技有限公司 | Serum-free and protein-free cell culture medium |
TW201934570A (en) * | 2017-07-06 | 2019-09-01 | 美商雷傑納榮製藥公司 | Cell culture process for making a glycoprotein |
KR20200037235A (en) | 2017-07-07 | 2020-04-08 | 박스알타 인코퍼레이티드 | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF |
WO2019010496A1 (en) | 2017-07-07 | 2019-01-10 | Baxalta Incorporated | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf |
US10934340B2 (en) | 2018-03-21 | 2021-03-02 | Baxalta Incorporated | Separation of VWF and VWF propeptide by chromatographic methods |
CN108872758B (en) * | 2018-05-10 | 2019-06-28 | 江苏大学 | A kind of electronic component life detecting device |
CA3128498A1 (en) | 2019-02-01 | 2020-08-06 | Bjorn Mellgard | Methods of prophylactic treatment using recombinant vwf (rvwf) |
WO2020201296A1 (en) | 2019-04-01 | 2020-10-08 | The Automation Partnership (Cambridge) Ltd. | Operation process for a cell cultivation system |
JP2022547556A (en) | 2019-09-11 | 2022-11-14 | 武田薬品工業株式会社 | Therapies involving the complex of von Willebrand factor and complement C1Q |
WO2021158777A1 (en) | 2020-02-04 | 2021-08-12 | Baxalta Incorporated | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf |
MX2023008527A (en) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Methods of improving protein titer in cell culture. |
CN113151183A (en) * | 2021-04-21 | 2021-07-23 | 赵峻岭 | Culture medium additive for promoting protein expression and application thereof |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT165999B (en) | 1947-06-26 | 1950-05-25 | Delle Atel Const Electr | Device for protecting three-phase motors against overcurrent |
US4443540A (en) * | 1980-05-09 | 1984-04-17 | University Of Illinois Foundation | Protein hydrolysis |
DK207980A (en) * | 1980-05-13 | 1981-11-14 | Novo Industri As | PROCEDURE FOR THE PREPARATION OF A FOAM OR EMERGENCY FOUNDANT ON SOY PROTEIN BASIS |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
FR2543158B1 (en) | 1983-03-24 | 1985-11-15 | Inst Nat Sante Rech Med | MEDIUM FOR CULTURING ANIMAL CELLS WITHOUT SERUM, WITHOUT HORMONES AND WITHOUT GROWTH FACTORS AND METHODS OF PRIMARY CULTURE AND OF OBTAINING CELL LINES USING THE SAME |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
IL74909A (en) | 1984-04-20 | 1992-01-15 | Genentech Inc | Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein |
WO1986004920A1 (en) | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
US4978616A (en) * | 1985-02-28 | 1990-12-18 | Verax Corporation | Fluidized cell cultivation process |
DE3787805T2 (en) | 1986-08-04 | 1994-02-10 | Garvan Inst Med Res | SERUM-FREE TISSUE CULTURE MEDIUM CONTAINING A POLYMER CELL PROTECTIVE. |
US5045468A (en) | 1986-12-12 | 1991-09-03 | Cell Enterprises, Inc. | Protein-free culture medium which promotes hybridoma growth |
AU627427B2 (en) | 1987-06-30 | 1992-08-27 | Amgen, Inc. | Production of kallikrein |
JP2507882B2 (en) | 1988-02-17 | 1996-06-19 | 工業技術院長 | Method for producing cell line with good growth independent of external growth factor |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
SE465222C5 (en) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | A recombinant human factor VIII derivative and process for its preparation |
DE69123140T2 (en) | 1990-01-22 | 1997-04-03 | The United States of America, represented by the Secretary, U.S. Department of Commerce, Washington, D.C. | CO-INDEPENDENT NUTRITIONAL MEDIUM FOR THE HOLDING AND REPRODUCTION OF CELLS |
JP2844484B2 (en) | 1990-02-22 | 1999-01-06 | 味の素株式会社 | Method for producing recombinant protein |
JP2859679B2 (en) | 1990-03-01 | 1999-02-17 | 協和醗酵工業株式会社 | New cell line |
US5378612A (en) * | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
JP2696001B2 (en) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | Medium for recombinant protein production |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
CA2053433C (en) | 1990-10-19 | 1997-03-25 | Michael Joseph Garvey | Detergent compositions |
JPH04228066A (en) | 1990-10-23 | 1992-08-18 | Rikagaku Kenkyusho | Culture cell for expressing exogenote |
EP0531562A1 (en) * | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Culturing of mammalian cells |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
JPH05123178A (en) | 1991-11-01 | 1993-05-21 | Ajinomoto Co Inc | Production of l-phenylalanine |
DE4313620A1 (en) | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamster cell lines and methods for glycoprotein recovery |
AU7895898A (en) | 1993-04-26 | 1998-10-08 | Hans Wolf | Mammal cell lines and method of obtaining glycoproteins |
GB9311132D0 (en) * | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
US5405637A (en) | 1993-06-30 | 1995-04-11 | Bristol-Myers Squibb Company | Milk protein partial hydrolysate and infant formula containing same |
JP2766165B2 (en) | 1993-08-02 | 1998-06-18 | 株式会社バイオポリマー・リサーチ | Method for producing bacterial cellulose |
US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
EP0653487A1 (en) | 1993-11-07 | 1995-05-17 | Ferruccio Dr. Messi | Serum and protein-free growing cells |
US5719050A (en) * | 1993-12-24 | 1998-02-17 | Eiken Chemical Co., Ltd. | Animal cell culturing media containing N-acetyl-L-glutamic acid |
US5498599A (en) * | 1994-01-21 | 1996-03-12 | Amgen Inc. | Methods for stimulating platelet production |
EP0666312A1 (en) * | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
EP0733100A1 (en) | 1994-09-09 | 1996-09-25 | Wolfgang A. Renner | Chemical process for promoting the proliferation of animal cells |
DK1213030T3 (en) | 1994-11-10 | 2009-07-20 | Baxter Healthcare Sa | Process for the preparation of biological products in protein-free culture |
AT403167B (en) | 1994-11-14 | 1997-11-25 | Immuno Ag | SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM |
WO1996018734A1 (en) | 1994-12-16 | 1996-06-20 | Novartis Ag | Production of recombinant secretory component |
WO1996026266A1 (en) | 1995-02-23 | 1996-08-29 | Quest International B.V. | Peptides for tissue and cell culture media |
US5741705A (en) * | 1995-02-23 | 1998-04-21 | Quest International Flavors & Food Ingredients Company, Division Of Indopco, Inc. | Method for in vitro cell growth of eucaryotic cells using low molecular weight peptides |
AU6125396A (en) | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
JP2000517188A (en) | 1996-08-30 | 2000-12-26 | ライフ テクノロジーズ,インコーポレイテッド | Serum-free mammalian cell culture medium and uses thereof |
AU4081997A (en) | 1996-08-30 | 1998-03-19 | University Of North Carolina At Chapel Hill, The | Immortalized human hepatic cell line |
ATE399855T1 (en) | 1996-10-10 | 2008-07-15 | Invitrogen Corp | ANIMAL CELL CULTURE MEDIUM WITH PLANT NUTRIENTS |
US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
ES2293681T3 (en) | 1997-05-28 | 2008-03-16 | Novartis Vaccines And Diagnostics S.R.L. | CROP MEANS WITH SOYA EXTRACT AS A SOURCE OF AMINO ACIDS BUT WITHOUT PROTEIN COMPLEXES OF ANIMAL ORIGIN. |
AT407255B (en) * | 1997-06-20 | 2001-02-26 | Immuno Ag | RECOMBINANT CELL CLONE WITH INCREASED STABILITY IN SERUM- AND PROTEIN-FREE MEDIUM AND METHOD FOR OBTAINING THE STABLE CELL CLONE |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
WO1999005268A1 (en) | 1997-07-23 | 1999-02-04 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
AU731857B2 (en) | 1997-11-20 | 2001-04-05 | Weyerhaeuser Company | Nutritive media and manufactured seeds comprising same |
AU2113199A (en) * | 1998-01-12 | 1999-07-26 | Betagene, Inc. | Media for neuroendocrine cells |
FR2775983B1 (en) | 1998-03-13 | 2000-11-10 | Pasteur Merieux Serums Vacc | VIRAL PROPAGATION AND MULTIPLICATION MEDIUM AND METHOD |
WO1999057246A1 (en) | 1998-05-01 | 1999-11-11 | Life Technologies, Inc. | Animal cell culture media comprising non-animal or plant-derived nutrients |
US6537782B1 (en) * | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
JP4266055B2 (en) | 1999-03-04 | 2009-05-20 | 雪印乳業株式会社 | Process for producing polyamine composition |
AT409379B (en) * | 1999-06-02 | 2002-07-25 | Baxter Ag | MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE |
DE59913565D1 (en) | 1999-08-05 | 2006-07-27 | Baxter Ag | RECOMBINANT STABLE CELL CLONE, ITS MANUFACTURE AND USE |
DK1210411T3 (en) | 1999-08-25 | 2007-02-19 | Immunex Corp | Compositions and Methods for Improved Cell Culture |
US6596526B1 (en) * | 2000-06-09 | 2003-07-22 | Baxter Aktiengesellschaft | Furin polypeptides with improved characteristics |
WO2002024876A2 (en) | 2000-09-25 | 2002-03-28 | Polymun Scientific Immunbiologische Forschung Gmbh | Live influenza vaccine and method of manufacture |
EP1208966A1 (en) | 2000-11-27 | 2002-05-29 | Cheng-Kun Liao | Manufacturing process of patio tabletop glass with broken protection |
DE10059175A1 (en) | 2000-11-29 | 2002-06-20 | Siemens Ag | Method for diverting calls in a communications system with multiple terminals connects to a local area network for activating call rerouting from one terminal to another, for transferring information and for diverting a call. |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
US6734289B2 (en) * | 2001-03-29 | 2004-05-11 | The University Of Chicago | Gastrokines and derived peptides including inhibitors |
JP2004532642A (en) | 2001-06-13 | 2004-10-28 | ジェネンテック・インコーポレーテッド | Animal cell culture method and polypeptide production in animal cells |
AU2002336367A1 (en) * | 2001-08-16 | 2003-03-03 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
KR20040039472A (en) | 2001-10-02 | 2004-05-10 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Method for production of recombinant proteins in eukaryote cells |
US20030104527A1 (en) * | 2001-12-03 | 2003-06-05 | National Research Council Of Canada | Methylotrophic bacterium for the production of recombinant proteins and other products |
DE10161412A1 (en) * | 2001-12-13 | 2003-07-03 | Aventis Pharma Gmbh | Method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity |
CN100591759C (en) | 2002-07-09 | 2010-02-24 | 巴克斯特国际有限公司 | Animal protein free media for cultivation of cells |
FR2846005B1 (en) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | COMPOSITION FOR BIOLOGICAL ENVIRONMENT COMPRISING SODIUM ERYTHORBATE |
FR2846004B1 (en) | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | COMPOSITION FOR CULTIVATION OF CELLS, IN PARTICULAR ANIMAL OR TISSUE, COMPRISING POLYETHYLENE GLYCOL |
DE10333675A1 (en) | 2003-07-24 | 2005-03-03 | Aventis Pharma Deutschland Gmbh | Perfusion method for the production of erythropoietin |
ES2565077T3 (en) | 2003-10-10 | 2016-03-31 | Novo Nordisk Health Care Ag | Method for large-scale production of a polypeptide in eukaryotic cells |
TWI384069B (en) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | Production of polypeptides |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
JP2008518597A (en) | 2004-10-29 | 2008-06-05 | セントカー・インコーポレーテツド | Chemically defined medium composition |
EP3653699A1 (en) | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
-
2007
- 2007-01-03 EP EP19214402.0A patent/EP3653699A1/en active Pending
- 2007-01-03 CN CNA2007800017871A patent/CN101360820A/en active Pending
- 2007-01-03 DK DK12160789T patent/DK2522717T3/en active
- 2007-01-03 JP JP2008548995A patent/JP5259418B2/en active Active
- 2007-01-03 CN CN2012100603866A patent/CN102643777A/en active Pending
- 2007-01-03 AU AU2007204044A patent/AU2007204044B2/en active Active
- 2007-01-03 WO PCT/EP2007/000027 patent/WO2007077217A2/en active Application Filing
- 2007-01-03 RU RU2008131953/10A patent/RU2486236C2/en active
- 2007-01-03 PT PT77025740T patent/PT1974014T/en unknown
- 2007-01-03 ES ES07702574.0T patent/ES2629304T3/en active Active
- 2007-01-03 EP EP20120160789 patent/EP2522717B1/en not_active Revoked
- 2007-01-03 DK DK07702574.0T patent/DK1974014T3/en active
- 2007-01-03 PT PT161839873T patent/PT3121266T/en unknown
- 2007-01-03 ES ES12160789.9T patent/ES2474573T3/en active Active
- 2007-01-03 PT PT121607899T patent/PT2522717E/en unknown
- 2007-01-03 US US11/649,694 patent/US20070212770A1/en not_active Abandoned
- 2007-01-03 KR KR1020137022322A patent/KR101422435B1/en active IP Right Grant
- 2007-01-03 PL PL07702574T patent/PL1974014T3/en unknown
- 2007-01-03 KR KR1020087018889A patent/KR101423344B1/en active IP Right Grant
- 2007-01-03 PL PL16183987T patent/PL3121266T3/en unknown
- 2007-01-03 HU HUE07702574A patent/HUE032744T2/en unknown
- 2007-01-03 EP EP07702574.0A patent/EP1974014B1/en not_active Revoked
- 2007-01-03 DK DK16183987.3T patent/DK3121266T3/en active
- 2007-01-03 EP EP16183987.3A patent/EP3121266B8/en not_active Revoked
- 2007-01-03 CA CA002633306A patent/CA2633306A1/en not_active Abandoned
- 2007-01-03 PL PL12160789T patent/PL2522717T3/en unknown
- 2007-01-03 LT LTEP07702574.0T patent/LT1974014T/en unknown
- 2007-01-03 SI SI200731439T patent/SI2522717T1/en unknown
- 2007-01-03 ES ES16183987T patent/ES2790887T3/en active Active
-
2011
- 2011-02-25 US US13/035,696 patent/US20110151512A1/en not_active Abandoned
-
2013
- 2013-03-01 JP JP2013040650A patent/JP2013106616A/en not_active Withdrawn
- 2013-03-18 RU RU2013112019A patent/RU2642269C9/en active
- 2013-05-13 HK HK13105678A patent/HK1177950A1/en unknown
-
2014
- 2014-10-15 JP JP2014210677A patent/JP2015006209A/en not_active Withdrawn
-
2015
- 2015-11-16 US US14/942,771 patent/US9758568B2/en active Active
-
2016
- 2016-12-28 JP JP2016254914A patent/JP6567490B2/en active Active
-
2017
- 2017-06-07 CY CY20171100596T patent/CY1119046T1/en unknown
- 2017-08-07 US US15/670,217 patent/US10696731B2/en active Active
- 2017-12-18 RU RU2017144220A patent/RU2758802C2/en not_active Application Discontinuation
-
2018
- 2018-01-09 JP JP2018001241A patent/JP2018075032A/en not_active Withdrawn
-
2019
- 2019-11-29 JP JP2019216735A patent/JP7134157B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of EP1974014A2 * |
Cited By (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10696731B2 (en) | 2006-01-04 | 2020-06-30 | Baxalta GmbH | Oligopeptide-free cell culture media |
EP1974014B1 (en) | 2006-01-04 | 2017-04-19 | Baxalta Incorporated | Oligopeptide-free cell culture media |
EP3121266B1 (en) | 2006-01-04 | 2020-02-26 | Baxalta Incorporated | Oligopeptide-free cell culture media |
JP2011507551A (en) * | 2007-12-27 | 2011-03-10 | バクスター・インターナショナル・インコーポレイテッド | Cell culture process |
WO2009087087A1 (en) * | 2008-01-09 | 2009-07-16 | Cellca Gmbh | Improved culture media additive and process for using it |
JP2011509089A (en) * | 2008-01-09 | 2011-03-24 | セルカ ゲーエムベーハー | Improved culture medium additive and method of using the same |
CN102317440A (en) * | 2008-01-09 | 2012-01-11 | 塞尔卡有限公司 | Improved culture medium additive and application method thereof |
EP2250251B1 (en) | 2008-01-09 | 2017-11-22 | Sartorius Stedim Cellca GmbH | Improved culture media additive and process for using it |
US8637312B2 (en) | 2008-01-09 | 2014-01-28 | Cellca Gmbh | Mammalian culture media with polyamine and iron |
EP2356247B2 (en) † | 2008-11-12 | 2019-05-15 | Baxalta Incorporated | Method of producing serum-free insulin-free factor vii |
EP2356247B1 (en) | 2008-11-12 | 2015-07-15 | Baxter International Inc. | Method of producing serum-free insulin-free factor vii |
JP2019201661A (en) * | 2009-07-31 | 2019-11-28 | バクスアルタ ゲーエムベーハー | Cell culture medium for ADAMTS protein expression |
US9441216B2 (en) | 2009-07-31 | 2016-09-13 | Baxalta Incorporated | Cell culture medium for ADAMTS protein expression |
WO2011014838A1 (en) | 2009-07-31 | 2011-02-03 | Baxter International Inc. | Cell culture medium for adamts protein expression |
US8759026B2 (en) | 2009-07-31 | 2014-06-24 | Baxter International Inc. | Methods for increasing recovery of an ADAMTS activity from a cell culture supernatant |
US9127265B2 (en) | 2009-07-31 | 2015-09-08 | Baxalta Incorporated | Cell culture medium for ADAMTS protein expression |
JP7083059B2 (en) | 2009-07-31 | 2022-06-09 | 武田薬品工業株式会社 | Cell culture medium for ADAMTS protein expression |
JP2021112210A (en) * | 2009-07-31 | 2021-08-05 | バクスアルタ ゲーエムベーハー | Cell culture medium for ADAMTS protein expression |
JP2014061005A (en) * | 2009-07-31 | 2014-04-10 | Baxter Internatl Inc | Cell culture medium for adamts protein expression |
JP2016144471A (en) * | 2009-07-31 | 2016-08-12 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | Cell culture medium for ADAMTS protein expression |
US10724024B2 (en) | 2009-07-31 | 2020-07-28 | Baxalta Incorporated | Cell culture methods for expressing ADAMTS protein |
US10221400B2 (en) | 2009-07-31 | 2019-03-05 | Baxalta GmbH | Method of producing a polypeptide or virus of interest in a continuous cell culture |
US11254921B2 (en) | 2009-07-31 | 2022-02-22 | Takeda Pharmaceutical Company Limited | ADAMTS13 protein cell culture supernatant |
US10745672B2 (en) | 2009-07-31 | 2020-08-18 | Baxalta Incorporated | Method of producing a polypeptide or virus of interest in a continuous cell culture |
US10072254B2 (en) | 2009-07-31 | 2018-09-11 | Baxalta Incorporated | Cell culture methods for expressing ADAMTS13 protein |
JP2018093881A (en) * | 2009-07-31 | 2018-06-21 | バクスアルタ ゲーエムベーハー | Cell culture medium for ADAMTS protein expression |
EP3167897A1 (en) | 2009-09-21 | 2017-05-17 | Baxalta GmbH | Stabilized liquid and lyophilized adamts13 formulations |
WO2011035335A2 (en) | 2009-09-21 | 2011-03-24 | Baxter International Inc. | Stabilized liquid and lyophilized adamts13 formulations |
EP3834841A1 (en) | 2009-09-21 | 2021-06-16 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized adamts13 formulations |
EP4218797A1 (en) | 2009-09-21 | 2023-08-02 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized adamts13 formulations |
EP2563903B1 (en) | 2010-04-26 | 2019-08-21 | Novartis AG | Improved cell culture medium |
US9834591B2 (en) | 2010-07-08 | 2017-12-05 | Baxalta Incorporated | Method of producing recombinant high molecular weight vWF in cell culture |
US10100099B2 (en) | 2010-07-08 | 2018-10-16 | Baxalta Incorporated | Method of producing recombinant high molecular weight vWF in cell culture |
WO2012006591A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE |
EP3909977A1 (en) | 2010-07-08 | 2021-11-17 | Takeda Pharmaceutical Company Limited | Method of producing recombinant adamts13 in cell culture |
WO2012006594A1 (en) | 2010-07-08 | 2012-01-12 | Baxter International Inc. | Method of producing recombinant adamts13 in cell culture |
US11780904B2 (en) | 2010-07-08 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Method of producing recombinant high molecular weight vWF in cell culture |
US8852888B2 (en) | 2010-07-08 | 2014-10-07 | Baxter International Inc. | Method of producing recombinant high molecular weight vWF in cell culture |
EP3626736A1 (en) | 2010-07-08 | 2020-03-25 | Baxalta GmbH | Method of producing recombinant high molecular weight vwf in cell culture |
US9409971B2 (en) | 2010-07-08 | 2016-08-09 | Baxalta Incorporated | Method of producing recombinant high molecular weight vWF in cell culture |
US9458222B2 (en) | 2010-07-08 | 2016-10-04 | Baxalta Incorporated | Method of producing recombinant ADAMTS13 in cell culture |
US10822394B2 (en) | 2010-07-08 | 2020-11-03 | Baxalta GmbH | Method of producing recombinant high molecular weight vWF in cell culture |
EP3392271A1 (en) | 2010-07-08 | 2018-10-24 | Baxalta GmbH | Method of producing recombinant adamts13 in cell culture |
US9505834B2 (en) | 2011-04-27 | 2016-11-29 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9365645B1 (en) | 2011-04-27 | 2016-06-14 | Abbvie, Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9957318B2 (en) | 2012-04-20 | 2018-05-01 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9708400B2 (en) | 2012-04-20 | 2017-07-18 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9683033B2 (en) | 2012-04-20 | 2017-06-20 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2906683B1 (en) | 2012-10-15 | 2017-05-31 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
EP2971040B1 (en) | 2013-03-14 | 2018-09-19 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9708399B2 (en) | 2013-03-14 | 2017-07-18 | Abbvie, Inc. | Protein purification using displacement chromatography |
KR20210031778A (en) * | 2013-03-15 | 2021-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
KR102278316B1 (en) | 2013-03-15 | 2021-07-19 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
US11332771B2 (en) | 2013-03-15 | 2022-05-17 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
KR20150128785A (en) * | 2013-03-15 | 2015-11-18 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
EP3378932A1 (en) * | 2013-03-15 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
EP3919611A1 (en) * | 2013-03-15 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
EP4159841A1 (en) * | 2013-03-15 | 2023-04-05 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
KR102166166B1 (en) | 2013-03-15 | 2020-10-15 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
KR20200119894A (en) * | 2013-03-15 | 2020-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
EP2970876B1 (en) | 2013-03-15 | 2018-07-11 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
WO2014144198A1 (en) * | 2013-03-15 | 2014-09-18 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
KR102229380B1 (en) | 2013-03-15 | 2021-03-18 | 리제너론 파마슈티칼스 인코포레이티드 | Serum-free cell culture medium |
US11970724B2 (en) | 2013-03-15 | 2024-04-30 | Regeneron Pharmaceuticals, Inc. | Serum-free cell culture medium |
EA037568B1 (en) * | 2013-03-15 | 2021-04-15 | Регенерон Фарматютикалз, Инк. | Serum-free cell culture medium and methods of use thereof |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9522953B2 (en) | 2013-10-18 | 2016-12-20 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9499616B2 (en) | 2013-10-18 | 2016-11-22 | Abbvie Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9688752B2 (en) | 2013-10-18 | 2017-06-27 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9550826B2 (en) | 2013-11-15 | 2017-01-24 | Abbvie Inc. | Glycoengineered binding protein compositions |
US11312936B2 (en) | 2015-08-04 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Taurine supplemented cell culture medium and methods of use |
US10927342B2 (en) | 2015-08-04 | 2021-02-23 | Regeneran Pharmaceuticals, Inc. | Taurine supplemented cell culture medium and methods of use |
WO2019204734A1 (en) | 2018-04-20 | 2019-10-24 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-il12/il23 antibody compositions |
US11079361B2 (en) | 2018-04-20 | 2021-08-03 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-IL12/IL23 antibody compositions |
WO2019204721A1 (en) | 2018-04-20 | 2019-10-24 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for produring anti-tnf antibody compositions |
US12018075B2 (en) | 2018-04-20 | 2024-06-25 | Janssen Biotech, Inc. | Chromatography column qualification in manufacturing methods for producing anti-TNF antibody compositions |
US11225516B2 (en) | 2018-04-20 | 2022-01-18 | Janssen Biotech, Inc. | Transition analysis method for chromatography column qualification |
US11634499B2 (en) | 2018-11-13 | 2023-04-25 | Janssen Biotech, Inc. | Control of trace metals during production of anti-CD38 antibodies |
WO2020100073A1 (en) | 2018-11-13 | 2020-05-22 | Janssen Biotech, Inc. | Control of trace metals during production of anti-cd38 antibodies |
WO2020183269A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2020183418A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
KR20220097421A (en) | 2019-11-05 | 2022-07-07 | 아지노모토 가부시키가이샤 | Methods for making proteins |
JPWO2021090888A1 (en) * | 2019-11-05 | 2021-05-14 | ||
JP7513034B2 (en) | 2019-11-05 | 2024-07-09 | 味の素株式会社 | Protein Production Methods |
WO2021090888A1 (en) | 2019-11-05 | 2021-05-14 | 味の素株式会社 | Method for producing protein |
US11286290B2 (en) | 2019-12-06 | 2022-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11548932B2 (en) | 2019-12-06 | 2023-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11174283B2 (en) | 2019-12-06 | 2021-11-16 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US12054533B2 (en) | 2019-12-06 | 2024-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11299532B2 (en) | 2019-12-06 | 2022-04-12 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11306135B2 (en) | 2019-12-06 | 2022-04-19 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11104715B2 (en) | 2019-12-06 | 2021-08-31 | Regeneran Pharmaceuticals, Inc. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
US11098311B2 (en) | 2019-12-06 | 2021-08-24 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11098112B2 (en) | 2019-12-06 | 2021-08-24 | Regeneron Pharmnaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11053280B2 (en) | 2019-12-06 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11407813B2 (en) | 2019-12-06 | 2022-08-09 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11440950B2 (en) | 2019-12-06 | 2022-09-13 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11459373B2 (en) | 2019-12-06 | 2022-10-04 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11459374B2 (en) | 2019-12-06 | 2022-10-04 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11472861B2 (en) | 2019-12-06 | 2022-10-18 | Regeneron Pharmaceuticals, Inc. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
US11485770B2 (en) | 2019-12-06 | 2022-11-01 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11505594B2 (en) | 2019-12-06 | 2022-11-22 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11505593B2 (en) | 2019-12-06 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11535663B2 (en) | 2019-12-06 | 2022-12-27 | Regeneron Pharmaceuticals, Inc. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
US11542317B1 (en) | 2019-12-06 | 2023-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US11186625B2 (en) | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
US12054532B2 (en) | 2019-12-06 | 2024-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
WO2021112927A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
WO2021112924A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
WO2021112925A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
US11649273B2 (en) | 2019-12-06 | 2023-05-16 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
WO2021112928A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
US11732025B2 (en) | 2019-12-06 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
WO2021112929A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
US12012444B2 (en) | 2019-12-06 | 2024-06-18 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
WO2021112923A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmacetucals, Inc. | Anti-vegf protein compositions and methods for producing the same |
WO2021112926A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
US11753459B2 (en) | 2019-12-06 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
WO2021198781A2 (en) | 2020-04-02 | 2021-10-07 | Takeda Pharmaceutical Company Limited | Adamts13 variant, compositions, and uses thereof |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023281466A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2023167871A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
WO2023167855A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
WO2023167847A2 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Bioreactor for antibody production |
WO2023167852A2 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
WO2023167857A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Cell culture methods for antibody production |
WO2023167863A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
WO2023167850A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10696731B2 (en) | Oligopeptide-free cell culture media | |
EP2213724B1 (en) | Animal protein-free media for cultivation of cells | |
AU2011221414A1 (en) | Animal Protein-Free Media for Cultivation of Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780001787.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2633306 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2007702574 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007702574 Country of ref document: EP Ref document number: 5606/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008702 Country of ref document: MX Ref document number: 2008548995 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007204044 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087018889 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2008131953 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007204044 Country of ref document: AU Date of ref document: 20070103 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2007204044 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2007702574 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137022322 Country of ref document: KR |